

MEDTRONIC INC  
Form 8-K  
March 26, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 26, 2013

**Medtronic, Inc.**

(Exact name of Registrant as Specified in its Charter)

Minnesota  
(State or other jurisdiction  
of incorporation)

1-7707  
(Commission  
File Number)

41-0793183  
(IRS Employer  
Identification No.)

Edgar Filing: MEDTRONIC INC - Form 8-K

**710 Medtronic Parkway, Minneapolis,**

**Minnesota**  
**(Address of principal executive offices)**

**(763) 514-4000**

**55432**  
**(Zip Code)**

**(Registrant's telephone number, including area code):**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other Events.**

On March 26, 2013, Medtronic, Inc. (the Company) sold \$1,000,000,000 aggregate principal amount of its 1.375% Senior Notes due 2018 (the 2018 Notes), \$1,250,000,000 aggregate principal amount of its 2.750% Senior Notes due 2023 (the 2023 Notes), and \$750,000,000 aggregate principal amount of its 4.000% Senior Notes due 2043 (the 2043 Notes, together with the 2018 Notes and 2023 Notes, the Notes), pursuant to an Underwriting Agreement dated March 19, 2013 (the Underwriting Agreement), among the Company, Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein. The Company's representations in the Underwriting Agreement were made as of the date thereof in connection with negotiating the contract, are subject to qualifications and limitations agreed to by the parties, may have been used for purposes of allocating risk between the parties rather than for the purpose of establishing matters as facts, and should not be relied upon as though such representations were made to any holders of securities of the Company. Investors should read the information provided in the Registration Statement (as defined below) and in the Company's other filings with the Securities and Exchange Commission.

The Notes were issued pursuant to an Indenture dated March 12, 2009 (the Indenture), as supplemented by the Fifth Supplemental Indenture dated March 26, 2013 (the Fifth Supplemental Indenture), between the Company and Wells Fargo Bank, National Association, as trustee. The offer and sale of the Notes have been registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-3ASR (No. 333-179938) filed with the Securities and Exchange Commission on March 6, 2012, as supplemented by a Prospectus Supplement dated March 19, 2013 (collectively, the Registration Statement).

The purpose of this Current Report is to file with the Securities and Exchange Commission the Underwriting Agreement, the Fifth Supplemental Indenture, which includes the form of Global Notes, and the legal opinion and consent of Fredrikson & Byron, P.A., copies of which are attached hereto as Exhibits 1.1, 4.1, and 5.1, respectively. A copy of the press release related to this offering is also furnished as Exhibit 99.1.

The foregoing description of the issuance, sale and terms of the Notes does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, the Indenture and the Fifth Supplemental Indenture entered into in connection therewith.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

- 1.1 Underwriting Agreement, dated March 19, 2013, among the Company, Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein.
- 4.1 Fifth Supplemental Indenture, dated March 26, 2013, between the Company and Wells Fargo Bank, National Association, as trustee (which includes the form of Global Notes).
- 5.1 Opinion of Fredrikson & Byron, P.A.
- 23.1 Consent of Fredrikson & Byron, P.A. (included in Exhibit 5.1).
- 99.1 Press Release of the Company dated March 19, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTRONIC, INC.

Date: March 26, 2013

By /s/ Gary L. Ellis  
Gary L. Ellis  
Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Medtronic, Inc.

Form 8-K Current Report

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 1.1                | Underwriting Agreement, dated March 19, 2013, among the Company, Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein. |
| 4.1                | Fifth Supplemental Indenture, dated March 26, 2013, between the Company and Wells Fargo Bank, National Association, as trustee (which includes the form of Global Notes).   |
| 5.1                | Opinion of Fredrikson & Byron, P.A.   |
| 23.1               | Consent of Fredrikson & Byron, P.A. (included in Exhibit 5.1).  |
| 99.1               | Press Release of the Company dated March 19, 2013.  |